Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Sam Isaly leaves OrbiMed months after harassment allegations

  • Damian Garde

By Damian Garde April 27, 2018

Reprints
Isaly CNBC Screen Cap
Sam Isaly has stepped down from OrbiMed Advisors. Screen capture via CNBC

More than four months after promising to resign from biotech’s most powerful hedge fund, Sam Isaly has stepped down from OrbiMed Advisors in the wake of allegations of rampant sexual harassment.

Isaly, 73, has transferred his control of the $14 billion fund to three of the firm’s partners, OrbiMed said in a statement. Sven Borho, Carl Gordon, and Jonathan Silverstein will lead OrbiMed from now on, the firm said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Covid-19 overtakes 1918 Spanish flu as deadliest disease in…
Covid-19 overtakes 1918 Spanish flu as deadliest disease in American history
A quest to explain the whooshing in her head
A quest to explain the whooshing in her head
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s…
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

Comments are closed.

Recommended Stories